GlassScriptPhysician profile
Alison Mae Bennett
NPI 1710694088
$2,499.59
in general payments reported to CMS, 2019-2025
30 companies · $65.31 in 2025
The $65.31 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $1,661 · 2024: $507 · 2025: $65.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $526.29 | 2023-2025 | Gocovri, Gocovri |
| Alexion Pharmaceuticals, INC. | $260.47 | 2022-2024 | Ultomiris, Soliris |
| Abbvie INC. | $200.22 | 2023-2024 | |
| Biogen, INC. | $146.12 | 2022-2023 | Vumerity, Plegridy, Tysabri |
| Pfizer INC. | $142.75 | 2023-2024 | |
| Ucb, INC. | $113.09 | 2023-2024 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $99.46 | 2023 | |
| Lilly USA, LLC | $84.11 | 2023-2024 | Amyvid, Emgality |
| Merz Pharmaceuticals, LLC | $81.25 | 2023 | Xeomin |
| Neurocrine Biosciences, INC. | $77.99 | 2023-2024 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $71.77 | 2023 | Lyvispah, Rytary |
| Avion Pharmaceuticals | $64.96 | 2022-2023 | Dhivy |
| Teva Pharmaceuticals USA, INC. | $62.43 | 2023 | Austedo, Austedo Xr |
| Tg Therapeutics, INC. | $56.85 | 2023 | |
| Acadia Pharmaceuticals INC | $54.96 | 2022-2024 | Nuplazid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $52.77 | 2023 | Valtoco |
| Impel Pharmaceuticals INC. | $52.65 | 2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $46.66 | 2023-2024 | Firdapse |
| Argenx US, INC. | $40.25 | 2023 | Vyvgart Hytrulo |
| Eisai INC. | $36.40 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $33.62 | 2023 | Dysport |
| Acorda Therapeutics, INC | $33.23 | 2023-2024 | Inbrija |
| Axsome Therapeutics, INC. | $27.75 | 2023 | Sunosi |
| Kyowa Kirin, INC. | $25.28 | 2024 | Nourianz |
| Microtransponder, INC. | $21.88 | 2023 | |
| Lundbeck LLC | $21.74 | 2023 | Rexulti |
| Emd Serono, INC. | $18.51 | 2023 | Mavenclad |
| Idorsia Pharmaceuticals US INC | $17.29 | 2023 | Quviviq |
| Amgen INC. | $14.66 | 2024 | Aimovig |
| Aucta Pharmaceuticals, INC. | $14.18 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.